Establishing trust and reaching your audience: The CGT Medical communications playbook

 

Establish trust through consistency and transparency

In medicine, trust is everything. Patients and caregivers need to trust that providers are offering the best possible care, while clinicians must be able to confidently stand by the treatments they prescribe. As medical communicators, we help build and sustain trust among clinicians, patients, caregivers, payers, and other healthcare decision-makers. In the rapidly evolving fields of cell and gene therapy, where there is a belief gap between scientific possibility and stakeholder confidence, that responsibility carries even greater weight.

As medical communicators, we know that trust in any therapy—is built through consistent and candid storytelling. This means adhering to a single narrative that is scientifically rigorous, transparent about uncertainty, and grounded in the realities of clinical practice while balancing aspirational visions. As stakeholders become more aware of the cell or gene therapies (CGTs) at their disposal (and increasingly understand the nuances of these two product categories), communicators must resist the temptation to overstate their promise. Terms such as ‘one-time treatment,’ ‘transformative therapy,’ or ‘potential cure’ are compelling, but they require careful framing when long-term evidence is still emerging.

Effective communication will strike a balance between optimism and evidence. This means avoiding the oversimplification of risks, acknowledging unanswered questions, and recognizing the practical constraints that can affect patient access and treatment delivery. Narratives that ignore reimbursement challenges, infrastructure requirements, or patient eligibility considerations risk undermining credibility with key stakeholders. Instead, organizations should prioritize a cohesive approach to storytelling across all communications.

The science is specialized. The communications strategy should be too.

CGTs are unique. They serve highly specific patient populations, involve complex treatment pathways, and require engaging with a diverse set of stakeholders with distinct informational needs. The communications strategies around them should reflect this complexity; the ‘wide net’ approach to awareness and education that works in other therapeutic areas won’t necessarily work for CGTs.

Different stakeholders may require different formats or framing, but the overarching story should be the same across audiences. Achieving this level of alignment requires close collaboration across medical affairs (including publications), market access, and health economics and outcomes research teams. Together, these functions can ensure that scientific evidence, clinical value, and real-world implementation considerations are reflected in a cohesive and credible narrative.

Success depends not on reaching the largest audience, but on delivering the right information to the right audience at the right time.

Building a cohesive scientific platform and narrative

Medical teams play a critical role in translating complex science into credible, evidence-based narratives that patients, caregivers, and providers can understand and trust. Medical communication and education must clearly address durability expectations, long-term follow-up needs, safety monitoring requirements, patient selection criteria, referral and treatment pathways, manufacturing considerations, and the practical realities of delivering highly specialized therapies. At the same time, communications must acknowledge where evidence is still evolving, particularly as CGTs move from controlled clinical trial settings into real-world practice.

A scientific communication platform (SCP) is a critical part of this work. For organizations aiming to bring CGTs to market, SCPs offer a framework to organize evidence, references, key messages, and approved (and agreed) scientific language to support consistent, transparent, and balanced communication across target audiences in a way that reflects internal cross-functional perspectives. The SCP enables publications, field medical tools, KOL engagement, core decks, education resources, and multichannel content to all stem from a shared scientific foundation. This is especially important in CGT, where inconsistent supporting evidence for concepts such as “one-time treatment,” “durable response,” “transformative benefit,” or “potential cure” can quickly undermine credibility. By aligning teams around evidence-based terminology and prioritized story points, the SCP helps ensure that every tactic reinforces the same balanced narrative while still allowing messages to be tailored to the needs of specific audiences.

Importantly, the SCP should be treated as a living document. As new clinical data, real-world evidence, long-term follow-up findings, safety updates, access insights, and publication outputs become available, the platform should evolve. In this way, the SCP acts as a single source of truth, helping organizations bring the narrative to life in the public domain piece by piece while maintaining the consistency, transparency, and scientific rigor needed to build trust around CGTs.

One key nuance is that many CGT organizations are building multiple assets from a shared scientific approach or modality. The risk is that stakeholders may form opinions about the broader approach based on one product’s results (positive or negative). A strong SCP therefore needs establish a consistent overarching narrative around the broader scientific approach while also supporting evidence-based, indication-specific communications for individual therapies. This ensures that stakeholders receive a coherent story across the portfolio, while still recognizing the unique clinical realities, evidence base, and patient needs associated with each disease area.

Turning CGT innovation into patient impact

As innovative approaches in science and technology allow CGTs to be explored in new patient populations, communication strategies must become increasingly precise and stakeholder specific.  For example, gene-editing therapies for sickle cell disease and beta-thalassemia bring together significant unmet need, health equity considerations, complex access challenges, and the potential for transformative long-term value. The approval of CAR-T for rare diseases with limited treatment options further demonstrates how these technologies are moving beyond traditional therapeutic boundaries.

Across the CGT landscape, organizations that can align medical, advisory, market access, and communications expertise will be best positioned to build understanding, support informed decision-making, and ultimately help translate scientific innovation into meaningful impact that reaches EVERY PATIENT POSSIBLE.